Semaglutide vs Liraglutide
Both are Novo Nordisk-manufactured long-acting GLP-1 receptor agonist analogues licensed for type 2 diabetes and obesity indications, with growing cognitive-endpoint research applications. Their positioning differs primarily on dosing frequency (once-weekly vs once-daily) and the specific Alzheimer's disease clinical-development stage (Phase III completed for semaglutide without slowing progression, Phase II completed for liraglutide).
At a glance
| Semaglutide | Liraglutide | |
|---|---|---|
| Structural class | Long-acting GLP-1 receptor agonist analogue | Long-acting GLP-1 receptor agonist analogue |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Dosing frequency | Once weekly (Ozempic / Wegovy) | Once daily (Victoza / Saxenda) |
| Licensed indications | Type 2 diabetes (Ozempic, Rybelsus), weight management (Wegovy) | Weight management (Saxenda); type 2 diabetes (see MHRA Drug Safety Update) |
| UK status | Authorised UK prescription-only medicine (emc) | Authorised UK prescription-only medicine (emc) |
| Cognitive-endpoint clinical trial | EVOKE Alzheimer's disease Phase III (completed; not efficacious in slowing progression, Lancet 2026) | ELAD Alzheimer's disease Phase II (completed, mixed results) |
| Signature cognitive-relevance research angle | Alzheimer's disease Phase III development trajectory | Alzheimer's disease Phase II mixed-results context |
| Evidence base — metabolic indication | Substantial licensed clinical use, large post-marketing safety base | Substantial licensed clinical use, large post-marketing safety base |
| Evidence tier — cognitive indication | B (Phase III completed; primary endpoint not met) | B (Phase II completed with mixed results) |
Alzheimer's disease clinical development
EVOKE Phase III versus ELAD Phase II — two data-points in the GLP-1 cognitive-endpoint trajectory
Semaglutide's Alzheimer's disease clinical-endpoint trajectory is represented by the EVOKE Phase III programme — two Phase III Alzheimer's disease trials of oral semaglutide in early Alzheimer's disease (NCT04777396 and NCT04777409). ClinicalTrials.gov lists both as completed (completion date 30 January 2026), and the Lancet report (Cummings et al., 2026) found that oral semaglutide was not efficacious in slowing clinical progression in early Alzheimer's disease.
Liraglutide's Alzheimer's disease clinical-endpoint trajectory is represented by the completed ELAD Phase II trial. The trial reported mixed results on cognitive-endpoint measures with modest effect estimates that did not reach primary-endpoint statistical significance in the full patient population but suggested possible benefit in specific subgroups. The trial provides a real data-point for the GLP-1 receptor agonist cognitive-effect prediction space.
For research applications the two clinical-development stages provide complementary data-points. ELAD's completed Phase II data provides preliminary clinical-context evidence already available for research design and hypothesis generation; EVOKE's Phase III results address the same mechanism-of-action angle at confirmatory scale and did not show slowed progression.
Practical usage considerations
Once-weekly versus once-daily dosing
The dosing-frequency difference is the primary practical positioning distinction between these compounds. Semaglutide's once-weekly injectable dosing provides substantial adherence advantages for chronic-indication clinical use — patients need to remember one injection per week rather than one per day. Liraglutide's once-daily dosing provides more granular dose-titration control which can be relevant in specific clinical contexts.
For cognitive-endpoint research applications the dosing-frequency difference is generally minor — the mechanism-of-action framing is essentially shared, the pharmacokinetic profiles deliver equivalent chronic GLP-1 receptor engagement, and the emerging cognitive-endpoint effects are anticipated to be substantially shared between the two compounds. Semaglutide's once-weekly convenience may make it more suitable for large-population cognitive-endpoint trial designs where adherence considerations matter.